Clerkenwell Health’s Post

📣 Initial positive results from our client Transcend Therapeutics are out! Methylone, which is a non-hallucinogenic neuroplastogen, produced rapid and durable effects in an open-label study of 14 participants with PTSD symptoms. 6 of these patients were recruited and dosed at our site in London - it was a privilege to see the improving wellbeing of these patients firsthand. 👉 Summary of results: Rapid: Almost 4 in 10 people achieved remission by day 10. Durable: By the end of the study, over 6 in 10 people achieved remission. No SAEs: No drug-related severe adverse effects (SAEs) occurred. A huge congratulations to everyone involved! We look forward to delivering the second part of this study. #methylone #clinicaltrials #clinicalstrial #drugdevelopment #ptsd #mentalhealth